Protocol Ledger

NCT06397313 · Phase II · TERMINATED

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

Interventional Phase II clinical trial protocol NCT06397313 sponsored by Ryvu Therapeutics SA in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-19 Enrollment: 36 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06397313
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)36 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06397313
Protocol FieldVerified Registry Value
NCT IdentifierNCT06397313
Consolidated Lead SponsorRyvu Therapeutics SA
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment36 participants (ACTUAL)
Registered Start Date2024-09-19
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI